Adequate ULT was defined as a mean daily dose of at least 300 mg of allopurinol and a duration of therapy of at least 2 years. Patients that had received adequate ULT were matched using propensity score on the basis of baseline eGFR and length of follow-up time to patients that received non-adequate ULT. Change from baseline in SU and eGFR was calculated and compared between groups.

Results: We identified 5433 patients with an incident gout diagnosis during 2000-2012 (and no gout diagnosis or prescription for ULT during 1997-1999).

Of these, 2393 (44%) received at least one prescription for allopurinol. SU was measured at some time point after initiation of ULT in 58% of patients. Adequate ULT as defined above was prescribed for 154 patients (3%), of these, 112 (73%) had a SU measurement at some time point after initiation of therapy and 35 (23%) had such a measurement done within 6 weeks of starting treatment. Matched controls could be identified for 109 of the patients with adequate ULT. Mean urate and eGFR at the start of therapy and end of follow up for the group with adequate ULT treatment and the controls are shown in table 1.

Table 1. Values are mean (SD) or n (%)

<table>
<thead>
<tr>
<th></th>
<th>Adequate ULT, n=154</th>
<th>Matched controls, n=109</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>66 (14)</td>
<td>68 (13)</td>
<td>0.19</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>25 (23)</td>
<td>38 (35)</td>
<td>0.05</td>
</tr>
<tr>
<td>Allpurinol daily dose in mg</td>
<td>359 (61)</td>
<td>119 (63)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>SU (Baseline)</td>
<td>511 (111)</td>
<td>509 (100)</td>
<td>0.91</td>
</tr>
<tr>
<td>eGFR (Baseline)</td>
<td>66 (21)</td>
<td>66 (21)</td>
<td>0.84</td>
</tr>
<tr>
<td>Length of follow-up, years</td>
<td>4.2 (3.5)</td>
<td>5.2 (3.9)</td>
<td>0.05</td>
</tr>
<tr>
<td>Δ SU (baseline compared to last available value)</td>
<td>-168 (153)</td>
<td>-78 (125)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Δ eGFR (baseline compared to last available value)</td>
<td>-1 (15)</td>
<td>-5 (16)</td>
<td>0.039</td>
</tr>
<tr>
<td>Last eGFR worse than baseline measurement, n (%)</td>
<td>50 (46)</td>
<td>67 (61)</td>
<td>0.021</td>
</tr>
</tbody>
</table>

Conclusion: ULT was prescribed to less than half of the patients identified. Adequate ULT was rare in clinical practice during the time period studied. Urate monitoring occurred in less than half of ULT-treated patients. The patients with adequate ULT achieved greater lowering of serum urate than matched controls and were more likely to maintain unchanged renal function over time.

Acknowledgement: Göran Rövall, database consultant.

Disclosure of Interests: Valgerdur Sigurdardottir: None declared, Lennart T.H. Jacobssson Consultant for: Lj has received lecture and consulting fees from Pfizer, Abbvie, Novartis, Eli-Lily and Janssen, Anna Svärd: None declared, Mats Dehlin: None declared


GOUT IN THE US: SIGNIFICANT ASSOCIATIONS WITH CARDIOVASCULAR AND RENAL DISEASE HOSPITALIZATIONS

Gurkispal Singh1,2, Maasneek Sehgal3, Alka Mithal4, 1ICORE, Woodside, United States of America; 2Stanford University, Palo Alto, United States of America; 3UCLA, Los Angeles, United States of America; 4ICORE, Woodside, United States of America

Background: Gout is a disorder of uric acid metabolism and often presents as acute severe joint pain. Previous work from our group suggests that all-cause hospitalizations in patients with gout in the United States (US) have significantly increased by almost hundred-fold of the 4.8% increase in US population all-cause hospitalization rate in the same time period. The current study focused on identifying potential reasons for the excess hospitalizations.

Objectives: To compare the primary reasons for hospitalizations in patients with gout to those in age-matched patients without gout in the US in 2016.

Methods: The Nationwide Inpatient Sample (NIS) is a stratified random sample of all US community hospitals. It is the only US national hospital database with information on all patients, regardless of payer, including persons covered by Medicare, Medicaid, private insurance, and the uninsured. We examined all inpatient hospitalizations in the NIS in 2016 among patients 40 years or older with a primary or secondary diagnosis of gout and compared them to total all-cause hospitalizations in patients without gout in the same age group during the same period. Over 69,800 ICD 10 diagnoses codes were collapsed into a smaller number of clinically meaningful categories, consistent with the Centers for Disease Control (CDC) Clinical Classification Software. The top 15 primary causes for hospitalization were evaluated and compared between the two cohorts.

Results: In 2016, there were 892,379 all-cause hospitalizations in the US in patients with gout with 14,135 (1.6%) of these for a primary diagnosis of gout. The primary diagnoses for 878,244 hospitalizations in patients with gout were compared with those in 21.9 million hospitalizations in the general US population without gout. The most common primary cause of hospitalizations in both cohorts was septicemia (7.8% in gout vs. 7.4% in general population). Significant differences were seen in several other categories. For example, acute renal failure was twice as frequent among gout patients (39,455 hospitalizations, 4.5%) compared to the general population (458,920 hospitalizations, 2.1%) (Relative Risk (RR) 2.11, 95% CI 2.08 – 2.13, p<0.0001). Hospitalizations for "hypertensive complications and secondary hypertension" were also higher (35,435, 4.0% in gout vs 370,400, 1.7% in general population, RR 2.35, 95% CI 2.32 – 2.37, p<0.0001). Hospitalizations from gastrointestinal bleeding were 30% more common in gout patients, perhaps associated with concomitant NSAID treatments (Figure).

Conclusion: Among patients with gout, a far greater proportion of serious hospitalizations are related to renal and cardiovascular complications as compared to age-matched general population. This calls for an increased awareness and management of serious co-morbid conditions in patients with gout.

REFERENCES


Figure

Primary reasons for comorbid hospitalizations more common in patients with gout compared with age-matched patients without gout, classified by Centers for Disease Control Clinical Classification Software (CDC CCS).

Acknowledgement: Supported in part by an unrestricted grant from Horizon Pharma

Disclosure of Interests: Gurkispal Singh Shareholder of: Merck, Pfizer, Grant/research support from: Horizon, Acorda, UCB, Consultant for: Horizon, Acorda, Sancilio, Unipharm, Maasneek Sehgal: None declared, Alka Mithal: None declared


MANAGEMENT OF GOUT: AN AUDIT IN PRIMARY CARE GENERAL PRACTICE IN LEICESTERSHIRE, UNITED KINGDOM

Ahmed Abo1, Larry Goodyer2, Neena Lakhani1, Muhammed Haider2, Kehinde Sunmboye1, 1DeMontfort University, Leicester School of Pharmacy, Leicester, United Kingdom; 2DeMontfort University, Leicester school of Pharmacy, Leicester, United Kingdom; 3University of Birmingham, Institute of Clinical sciences, Birmingham, United Kingdom; 4University Hospitals Of Leicester, Department of Rheumatology, Leicester, United Kingdom

Background: Both acute and long-term management of gout in primary care in UK is reportedly suboptimal1, with patients rarely being offered lifestyle advice or urate Lowering Therapy (ULT). Further,ULT is often not titrated according to the patient’s serum uric acid (sUA) levels, so that they fail to achieve target sUA levels.

Objectives: To audit and evaluate the management of gout in patients in a primary care setting against the current guidelines treat to target guidelines set by the British Society of Rheumatology (BSR)2.

SAT0446

SAT0447
Methods: Audit criteria were derived from the latest BSR gout guideline (Hui et al., 2017). A randomised sample of adult patients with a read code for gout from Jan 2006-Jan 2018 was chosen from six large general practices in Leicestershire County of the United Kingdom. The data collected included demographics, provision of patient information, management of acute attacks and prophylactic treatment, screening of appropriate co-morbidities, dosing of urate-lowering therapy (ULT) and titration of doses against measurement of uric acid levels.

Results: Data was obtained for 861 patients. The mean age was 60 years and 91% were male. 21.5% were recorded as being provided with written information about gout and 60.5% of patients were treated with NSAIDs and COXIBs for acute attacks of gout. When colchicine was prescribed to patients, 71% had no dose recorded in their clinical records. 323 (37.5%) of patients were prescribed a ULT and the recorded starting dose of allopurinol was 100mg daily for 73.8%. Titration was subsequently undertaken for subsequent doses was recorded in only 21% of patients. 539 patients (62.6%) had no record of a serum urate level check after starting ULT.

Conclusion: Clinical records indicate that the management of gout by UK General Practitioners in Primary Care is suboptimal in concordance with the BSR guidelines. It was clear that general practices did not employ the treat to target strategy. There is a clear need for increased GP awareness and adherence to the BSR guidelines in order to optimise deficient areas of care, particularly in patient education, initiation and titration of ULT and monitoring of serum urate levels in gout patients. Appropriate patient recording templates are needed so that key information is captured during a patient consultation in order to enable medicines optimisation for those with gout. Most aspects of gout management in primary care did not concord well with published BSR guidelines.

REFERENCES

Disclosure of Interests: None declared


SAT0448

ATP IS THE SECOND KEY SIGNAL OF GOUT FLARE BESIDES MSU

Hong-Liang Zhang1, Zi-Wen Zhu2, Jinhu Tao3, Yu-Jie Tang1, LI Xin-Ya1, LI Lin2, Qun-Qun Lu1, Hong-Liang Zhang2, Yi-Jie Tang3, Li Xin-Ya4, Zi-Wen Zhu5, Anhui Medical University Affiliated Provincial Hospital, hefei, China; 2Anhui Medical University Affiliated Provincial Hospital, hefei, China; 3Anhui Medical University Affiliated Provincial Hospital, hefei, China;

Background: Gout is an inflammatory disease associated with hyperuricemia and characterized by recurrent arthritis. In previous study, MSU which generated by hyperuricemia was recognized by the toll-like receptor and NOD receptor of the intrinsic immune system, then activated the NALP3 inflammasome to induce the secretion of IL-1β, causing gout. However, this mechanism can not explain why most patients with hyperuricemia do not have gout attacks in clinical practice, suggesting that there may be other pathogenic signals in the flare of gout. Our team previously found that P2X7R might play a key regulatory role in the pathogenesis of gout [1, 2]. What's more, single nucleotide polymorphisms associated with P2X7R function regulate the onset of gouty arthritis [3].

SAT0449

EFFECT OF CHOLESTEROL AND TRIGLYCERIDE ON THE FREQUENCY OF GOUT ATTACKS

Li Lin1, Qun-Qun Lu1, Jinhu Tao2, Hong-Liang Zhang2, Yu-Jie Tang3, Li Xin-Ya2, Zi-Wen Zhu5, Anhui Medical University Affiliated Provincial Hospital, Department of Rheumatology and Immunology, hefei, China; The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Department of Rheumatology and Immunology, hefei, China;

Background: Gout is an autoinflammatory disease characterized by hyperuricemia and recurrent arthritis. ATP and MSU synergistically activate NALP3 inflammasome to induce the secretion of IL-1β, leading to the onset of gouty arthritis, and P2X7R plays a key role in gout [3, 4]. This mechanism above can explain the clinical phenomenon that some patients with hyperuricemia never suffer gouty arthritis, however, it cannot explain why the frequency of gout attacks increases as the course prolongs. Cholesterol or triglyceride can activate the innate immune and induce inflammatory response. It is speculated that Cholesterol and triglyceride levels can increase with the duration of gout, and may reduce the threshold of gout attacks.

Objectives: To demonstrate the effect of elevated cholesterol and triglyceride on the onset of gout.

Methods: A cohort study was performed to observe the difference of arthritis episodes between the high cholesterol group and the normal, the high triglyceride group and the normal in gout patients. The frequency of gout attacks was compared using statistical methods of independent sample test and paired sample test between the two groups.

Results: A cohort study was performed to observe the difference of arthritis episodes between the high cholesterol group and the normal, the high triglyceride group and the normal in gout patients. The frequency of gout attacks was compared using statistical methods of independent sample test and paired sample test between the two groups.

RESULTS: A total of 68 patients with gout were observed. Among them, 21 were in normal cholesterol group, 13 in elevated group, 21 in normal triglyceride group and 13 in elevated group. The results of the independent sample test between the two groups are as follows: (1) The frequency of gout attacks between the normal cholesterol group and the elevated group is statistically significant within three months, six months and one year (0.81±0.60 vs 1.77±0.83, Z=3.300, P=0.001; 1.14±0.73 vs 3.15±2.15, Z=-3.430, P=0.001; 1.43±0.81 vs 4.77±3.44, Z=-3.199, P=0.001). (2) The frequency of gout attacks between the normal triglyceride group and the elevated group is statistically significant within three months, six months and one year (0.81±0.60 vs 1.54±0.97, Z=-2.359, P=0.018; 1.14±0.73 vs 2.38±1.66, Z=-2.417, P=0.016; 1.43±0.81 vs 3.54±2.50, Z=-3.005, P=0.003). The results of the paired sample test between